PTSD drug safety study halted early: what we know
NCT ID NCT04468360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small Phase 2 study aimed to test the safety and dosing of an intravenous drug called allopregnanolone (also known as brexanolone) in 11 people with chronic PTSD. The trial was terminated before completion, so results are limited. The main goal was to monitor sedation levels and vital signs, not to measure whether the drug reduces PTSD symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allopregnanolone (brexanolone)
- What this could lead to
- If successful, this could help determine safe dosing for future studies testing whether allopregnanolone can improve PTSD treatment.
- What could go wrong
- This was a very small, early-stage safety study that was terminated. It does not test whether the drug actually helps PTSD symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC STUDY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts, 02118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sensory training may rewire how veterans cope with PTSD
- Can a Two-Drug combo rewire the PTSD brain?
- Could lifestyle changes protect hearts in PTSD?
- A 4-session couples therapy aims to curb violence in veteran relationships
- Could a surgeon's mental health impact your surgery outcome?
- Zapping the brain with microcurrents may curb cravings — a trial puts it to the test